Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Biomet To Settle With DOJ, SEC On Bribery Charges For $22.7Mln

share with twitter share with LinkedIn share with facebook
share via e-mail
03/26/2012 | 05:50pm CET

Medical-device company Biomet Inc. has agreed to pay about $22.7 million to settle civil and criminal charges stemming from allegations the company's units and agents bribed public doctors in Argentina, Brazil and China for nearly a decade to win business, the Department of Justice and the Securities and Exchange Commission said Monday.

The agencies allege that Biomet and its four units paid bribes from 2000 to August 2008, and employees and managers at all levels of the parent company and the units were involved, along with distributors. Biomet's compliance and internal audit functions failed to stop the payments to doctors even after learning about the illegal practices, the agencies alleged.

A Biomet representative wasn't immediately available for comment.

Biomet agreed to pay a $17.3 million criminal penalty for allegedly violating the Foreign Corrupt Practices Act. In its Justice Department agreement, it is required to implement rigorous internal controls, cooperate fully with the Justice Department and retain a compliance monitor for 18 months. Additionally, the company will pay $5.4 million in disgorgement of profits and prejudgment interest, as part of its separate SEC settlement.

Biomet, a privately held company that sells products used by orthopedic surgeons, is the third medical device firm to enter into a settlement with government agencies as part of the SEC and Justice Department's ongoing global investigation into medical-device companies allegedly bribing publicly employed physicians. Previously, Johnson & Johnson (>> Johnson & Johnson) and Smith & Nephew PLC (SNN, SN.LN) agreed to pay criminal penalties and entered into deferred prosecution agreements related to similar investigations, the Justice Department said.

In January, Biomet said its fiscal second-quarter loss widened as a drop in spine and bone-healing sales as well as higher costs masked the company's revenue growth.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; [email protected]

Stocks mentioned in the article : Johnson & Johnson
Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -0.28% 129.82 Delayed Quote.-4.32%
SMITH & NEPHEW -0.30% 1317.5 Delayed Quote.2.48%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
02:25pJOHNSON & JOHNSON : to Host Investor Conference Call on First-Quarter Results
12:38pGlobal Brands Divided Over Transparency Efforts to Tackle Deforestation for P..
10:10aJOHNSON & JOHNSON : FDA shares data from first drug in transparency pilot
09:39aJOHNSON & JOHNSON : unveils plans for second turbine at Limerick facility
03/19JOHNSON & JOHNSON : Janssen Announces U.S. FDA Breakthrough Therapy Designation ..
03/19JOHNSON & JOHNSON : Announces Binding Offer from Platinum Equity to Acquire Life..
03/19JOHNSON & JOHNSON : Greenpeace says brands refusing to reveal palm oil sources
03/17JOHNSON & JOHNSON : FDA Breakthrough Therapy Designation for Erdafitinib in the ..
03/17JOHNSON & JOHNSON : Platinum Equity Submits Binding Offer to Acquire LifeScan Fr..
03/16JOHNSON & JOHNSON : J&J nears diabetes device exit with $2.1 bln LifeScan sale
More news
News from SeekingAlpha
09:11aProtalix Should Be Looked At After Positive Ulcerative Colitis Data 
03/19FIRST AMERICAN FINANCIAL : A Gem With Great Total Return And Steady Dividend Gro.. 
03/19DIVIDEND CHAMPIONS : 12 Increases Expected By The End Of May 
03/19Geron up 35% premarket on rosier outlook for imetelstat 
03/19Trump to release opioid epidemic plan 
Financials ($)
Sales 2018 81 115 M
EBIT 2018 24 940 M
Net income 2018 19 683 M
Debt 2018 12 439 M
Yield 2018 2,77%
P/E ratio 2018 18,08
P/E ratio 2019 16,97
EV / Sales 2018 4,46x
EV / Sales 2019 4,12x
Capitalization 349 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 150 $
Spread / Average Target 15%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-4.32%358 615
PFIZER1.55%218 946
NOVARTIS-6.12%214 541
ROCHE HOLDING LTD.-11.01%199 453
MERCK AND COMPANY-2.91%150 097
AMGEN8.25%135 639